Discussion of “A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III” by Andrew G. Chapple and Peter F. Thall (Q5214491)
From MaRDI portal
scientific article; zbMATH DE number 7165179
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Discussion of “A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III” by Andrew G. Chapple and Peter F. Thall |
scientific article; zbMATH DE number 7165179 |
Statements
Discussion of “A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III” by Andrew G. Chapple and Peter F. Thall (English)
0 references
7 February 2020
0 references
clinical trial design
0 references
